title: Cardiotoxicity Following Cancer Treatment.
abstract: More than half of those born after 1960 will develop cancer during their lifetime. Fortunately, owing to improved diagnosis and treatment, cure rates have risen steadily over the last three decades. With an increased survivorship, more will experience adverse effects of cancer therapeutics on the heart. As the oncologist's focus begins to encompass the issues of cancer survivorship, awareness of the management of cardiac toxicity would be prudent for all physicians looking after patients with cancer.
authors.affiliation: The Royal Marsden Hospital NHS Foundation Trust, Fulham Road, London.
authors.forename: G M
authors.initials: GM
authors.lastname: Walls
authors.affiliation: National Heart and Lung Institute, Imperial College London; NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London.
authors.forename: A R
authors.initials: AR
authors.lastname: Lyon
authors.affiliation: Centre for Experimental Medicine, Queen's University Belfast.
authors.forename: M T
authors.initials: MT
authors.lastname: Harbinson
authors.affiliation: Centre for Cancer Research and Cell Biology, Queen's University Belfast.
authors.forename: G G
authors.initials: GG
authors.lastname: Hanna
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D006331:Heart Diseases / Q000209:etiology*; D006801:Humans; D058990:Molecular Targeted Therapy / Q000009:adverse effects*; D009369:Neoplasms / Q000628:therapy*; D011878:Radiotherapy / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents